Last reviewed · How we verify
Ginkgo biloba extract EGb 761
Ginkgo biloba extract EGb 761 is a Phytotherapeutic Small molecule drug developed by VSM Geneesmiddelen b.v.. It is currently in Phase 2 development for Cognitive impairment in dementia, Alzheimer's disease. Also known as: Ginkgo biloba.
Ginkgo biloba extract EGb 761 is believed to improve blood flow to the brain by increasing nitric oxide production and reducing platelet aggregation.
Ginkgo biloba extract EGb 761 is believed to improve blood flow to the brain by increasing nitric oxide production and reducing platelet aggregation. Used for Cognitive impairment in dementia, Alzheimer's disease.
At a glance
| Generic name | Ginkgo biloba extract EGb 761 |
|---|---|
| Also known as | Ginkgo biloba |
| Sponsor | VSM Geneesmiddelen b.v. |
| Drug class | Phytotherapeutic |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action of EGb 761 is not fully understood, but it is thought to involve the inhibition of platelet-activating factor (PAF) and the enhancement of blood flow to the brain through the production of nitric oxide. This may be due to the antioxidant properties of the flavonoids and terpenoids present in the extract.
Approved indications
- Cognitive impairment in dementia
- Alzheimer's disease
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment (PHASE4)
- Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis (NA)
- Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin (NA)
- A Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI (PHASE2)
- Gastrodin Acupoint Injection for Sensorineural Hearing Loss With Vertigo (NA)
- Modifiable Risk Factors for Non-traumatic Subconjunctival Hemorrhage
- Efficacy and Safety of Ginkgo Biloba Extract EGb761® in Patients With Diabetic Retinopathy (PHASE2)
- Effects of Indena's Virtiva® Plus Ginkgo Biloba Extract on Stress, and Cognitive Performance (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ginkgo biloba extract EGb 761 CI brief — competitive landscape report
- Ginkgo biloba extract EGb 761 updates RSS · CI watch RSS
- VSM Geneesmiddelen b.v. portfolio CI
Frequently asked questions about Ginkgo biloba extract EGb 761
What is Ginkgo biloba extract EGb 761?
How does Ginkgo biloba extract EGb 761 work?
What is Ginkgo biloba extract EGb 761 used for?
Who makes Ginkgo biloba extract EGb 761?
Is Ginkgo biloba extract EGb 761 also known as anything else?
What drug class is Ginkgo biloba extract EGb 761 in?
What development phase is Ginkgo biloba extract EGb 761 in?
What are the side effects of Ginkgo biloba extract EGb 761?
Related
- Drug class: All Phytotherapeutic drugs
- Manufacturer: VSM Geneesmiddelen b.v. — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Cognitive impairment in dementia
- Indication: Drugs for Alzheimer's disease
- Also known as: Ginkgo biloba
- Compare: Ginkgo biloba extract EGb 761 vs similar drugs
- Pricing: Ginkgo biloba extract EGb 761 cost, discount & access